Irny 100mg Injection contains Ferric Carboxymaltose 100mg/2ml, an intravenous iron preparation indicated for the treatment of iron deficiency anemia when oral iron therapy is ineffective or cannot be used. Ferric Carboxymaltose provides a stable complex that allows controlled release of iron, facilitating rapid replenishment of iron stores and hemoglobin synthesis. This formulation is particularly beneficial in patients with chronic kidney disease, postpartum anemia, or those undergoing chemotherapy, where iron requirements are increased or absorption is impaired. Administration should be performed by healthcare professionals experienced in intravenous iron therapy, with dosage individualized based on patient weight, hemoglobin levels, and iron deficit. Irny 100mg Injection offers a favorable safety profile, with common adverse effects including transient hypotension, nausea, headache, and injection site reactions. Hypersensitivity reactions, although rare, necessitate close monitoring during and after administration. The product is contraindicated in patients with known hypersensitivity to ferric carboxymaltose or any excipients, and in cases of iron overload or disturbances in iron utilization. Proper patient assessment and monitoring of iron parameters are essential to optimize therapeutic outcomes and minimize risks. Irny 100mg Injection provides an effective and convenient option for rapid iron repletion in appropriate clinical settings.